RA Cap­i­tal backs a Philly biotech's $118M crossover as it aims to break in­to the hy­per­ten­sion space

While the hy­per­ten­sion mar­ket be­comes ever more crowd­ed with can­di­dates as J&J toss­es its hat in­to the ring, a Penn­syl­va­nia-based start­up is look­ing to carve its own path with back­ing from some no­table names at­tached.

Min­eralys Ther­a­peu­tics out of Philadel­phia has com­plet­ed a $118 mil­lion Se­ries B fi­nanc­ing with back­ing from RA Cap­i­tal Man­age­ment and An­dera Part­ners, the biotech an­nounced Wednes­day. The com­pa­ny plans to use the pro­ceeds to con­tin­ue ad­vanc­ing its lead drug can­di­date, MLS-101, for pa­tients with un­con­trolled hy­per­ten­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER